CAS: 61270-58-4; Cefonicid

该化合物是属于乙型抗生素类的半合成性脑肺炎抗生菌,主要用于治疗各种细菌感染,尤其是由抗菌素和一些抗菌菌菌引起的细菌感染;胆碱酯酶表现出广泛的活动,对Escherichia coli和Klebsiella肺炎等生物体有效;该化合物的特征是稳定地防治某些乙型乳腺,这提高了抗传染病的疗效;一般通过注射施用,而且已知其半衰期相对较长,允许较少的剂量服用,与其他一些抗生酶素相比,其药性活性与活性相对较低;其药用动力学学学涉及人体组织和液体的分布,而肾上排泄是主要消除途径;与其他抗生生素一样,潜在的副作用可能包括过敏反应,胃肠紊乱和正常植物的改变;总体而言,胆碱盐是抗生能库中用于控制细菌感染的一个重要选择,特别是在临床环境中.

结构式图片

MSDS等安全信息

    上下游产品

    (R)-methyl mandelate 7-amino-3-(1-sulfomethyl-1H-1,2,3,4-tetrazol-5-yl)thiomethyl-3-cephem-4-carboxylic acid

    合成工艺路线路线简述

      📜(R)-(-)-扁桃酸甲酯,(6R-反式)-7-氨基-8-氧代-3-(((1-(磺酸甲基)-1H-四唑-5-基)硫)甲基)-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸置于3G3K Penicillin G Acylase Immobilized On Glyoxyl Agarose体系中,化学反应生成 头孢尼西
      参考文献:定点诱变和固定化的耦合用于更高效生物催化剂的合理设计:来自大肠杆菌的固定化 3G3K Pga 的案例
      标题:定点诱变和固定化的耦合用于更高效生物催化剂的合理设计:来自大肠杆菌的固定化 3G3K Pga 的案例
      摘要:我们研究了通过定点诱变获得的来自大肠杆菌的青霉素 G 酰基转移酶 (Pga) 的固定化 3G3K 突变体的合成性能.3G3K 突变体的特征是由三个赖氨酸与 β 链末端的三个甘氨酸交替组成的标签,之前曾报道过抗生素合成速率和酰化剂水解速率的比率更高. Vs/vh1 值)比野生型酶.通过使用不同的乙醛基支持物(用醛基激活),对 3G3K 突变体进行了新的固定研究.在通过动力学控制的 N-酰化 (Kcna) 合成头孢曼多和头孢尼西的过程中测试了新固定化制剂的催化性能.与商业野生型 Pga 相比,
      DOI:10.1002/ejoc.200801204

      海关参考信息

      专利信息


      专利号:US-7199128-B2
      优先权日:2005-02-02
      标题 :8-N-substituted-2H-isothiazolo[5,4-b]quinolizine-3,4-diones and related compounds as antiinfective agents
      发明人:BRADBURY BARTON J; WILES JASON ALLAN; DESHPANDE MILIND; WANG QIUPING; HASHIMOTO AKIHIRO; LUCIEN EDLAINE
      权利人:ACHILLION PHARMACEUTICALS INC
      摘要:The invention provides compounds and salts of Formula I and Formula II: n nwhich possess antimicrobial activity. The invention also provides novel synthetic intermediates useful in making compounds of Formula I and Formula II. The variables A 1 , A 8 , R 2 , R 3 , R 5 , R 6 , R 7 , and R 9 are defined herein.n n Certain compounds of Formula I and Formula II disclosed herein are potent and selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula I or Formula II as the only active agent or may contain a combination of compounds of Formula I and/or Formula II and one or more other active agents. The invention also provides methods for treating microbial and protozoal infections in animals.

      专利号:US-2009012071-A1
      优先权日:2007-04-23
      标 题 :4-substituted-1h-isothiazolo[5,4-b][1,4]oxazino[2,3,4-ij]quinoline-7,8(2h,9h)-diones and related compounds as anti-infective agents
      发明人:BRADBURY BARTON JAMES; DESHPANDE MILIND; HASHIMOTO AKIHIRO; KIM HA YOUNG; LUCIEN EDLAINE; PAIS GODWIN; PUCCI MICHAEL JOHN; WANG QIUPING; WILES JASON ALLAN
      权利人:ACHILLION PHARMACEUTICALS INC
      摘要:The present invention provides compounds of the formula that possess antimicrobial activity. Certain compounds provided herein possess potent antibacterial, antiprotozoal, or antifungal activity. Particular compounds provided herein are also potent and/or selective inhibitors of microbial DNA synthesis and reproduction. The invention provides anti-microbial compositions, including pharmaceutical compositions, containing a compound of the invention and one or more or more carriers. The invention provides pharmaceutical compositions containing a 4-substituted- 1 H-isothiazolo[5,4-b][1,4]oxazino[2,3,4-ij]quinoline-7,8(2H,9H)-dione or related compound as the only active agent or in combination with one or more other active agents. The invention provides methods for treating or preventing microbial infections, preferably animals, by administering an effective amount of a 4-substituted- 1 H-isothiazolo[5,4-b][1,4]oxazino[2,3,4-ij]quinoline-7,8(2H,9H)-dione or related compound to an organism suffering from or susceptible to microbial infection. The invention also provides methods of inhibiting microbial growth and survival by applying an effective amount of a 4-substituted- 1 H-isothiazolo[5,4-b][1,4]oxazino[2,3,4-ij]quinoline-7,8(2H,9H)-dione or related compound.

      专利号:US-8946422-B2
      优先权日:2005-07-27
      标题:8-methoxy-9H-isothiazolo[5,4-B]quinoline-3,4-diones and related compounds as anti-infective agents
      发明人:BRADBURY BARTON JAMES; WILES JASON ALLAN; WANG QIUPING; HASHIMOTO AKHIRO; LUCIEN EDLAINE; PAIS GODWIN CLARENCE GILROY; DESHPANDE MILIND; PUCCI MICHEAL JOHN; KIM HA YOUNG
      权利人:BRADBURY BARTON JAMES; WILES JASON ALLAN; WANG QIUPING; HASHIMOTO AKHIRO; LUCIEN EDLAINE; PAIS GODWIN CLARENCE GILROY; DESHPANDE MILIND; PUCCI MICHEAL JOHN; KIM HA YOUNG; ACHILLION PHARMACEUTICALS INC
      摘要:The invention provides compound and salts of Formula I and II, disclosed herein, which includes compounds of Formula A and Formula B: Such compounds possess useful antimicrobial activity. The variables R2, R3, R5, R6, R7, and R9 shown in Formula A and B are defined herein. Certain compounds of Formula I and Formula II disclosed herein are potent and/or selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula I or Formula II as the only active agent or may contain a combination of a compound of Formula I or Formula II and one or more other active agents. The invention also provides methods for treating microbial infections in animals.

      专利号:US-7659399-B2
      优先权日:2005-01-05
      标 题 :1-thia-2,4a-diaza-cyclopenta[b]napththalene-3,4-diones and related compounds as anti-infective agents
      发明人:BRADBURY BARTON JAMES; WILES JASON ALLAN
      权利人:ACHILLION PHARMACEUTICALS INC
      摘要:The invention provides compounds and salts of Formula I and Formula II: n nwhich possess antimicrobial activity. The invention also provides novel synthetic intermediates useful in making compounds of Formula I and Formula II. The variables A 1 , A 8 , R 2 , R 3 , R 5 , R 6 , R 7 , and R 9 are defined herein.n n Certain compounds of Formula I and Formula II disclosed herein are potent and selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula I or Formula II as the only active agent or may contain a combination of a compound of Formula I or Formula II and one or more other active agents. The invention also provides methods for treating microbial infections in animals.

      专利号:EP-1809639-B1
      优先权日:2004-11-11
      标 题 :8a, 9-dihydro-4a-h-isothiazolo[5,4-b] quinoline-3, 4-diones and related compounds as anti-infective agents
      发明人:BRADBURY BARTON JAMES; DESHPANDE MILIND; PUCCI MICHAEL JOHN; WANG QIUPING; WILES JASON ALLAN; SONG YONGSHENG; HASHIMOTO AKIHIRO; LUCIEN EDLAINE
      权利人:ACHILLION PHARMACEUTICALS INC
      摘要:The invention provides compounds and salts of Formula I and Formula II: which possess antimicrobial activity. The invention also provides novel synthetic intermediates useful in making compounds of Formula I and Formula II. The variables n, m, p, RA, RB, A1, R2, R3, R5, R6, R7, A8 and R9 are defined herein. Certain compounds of Formula I and Formula II disclosed herein are potent and/or selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula I or Formula II as the only active agent or may contain a combination of a compound of Formula I or Formula II and one or more other active agents. The invention also provides methods for treating microbial infections in eukaryotes.

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      主要参考文献


      1: Badillo E, Escudero E, Hernandis V, Galecio JS, Marín P. Pharmacokinetics of cefonicid in lactating goats after intravenous, intramuscular and subcutaneous administration, and after a long-acting formulation for subcutaneous administration. J Vet Pharmacol Ther. 2020 Jan;43(1):50-56. doi: 10.1111/jvp.12825. Epub 2019 Nov 14. 32(3):222-59. doi: 10.2165/00003495-198632030-00002. 3(1):23-32. 2012–. Cephalosporins. 2017 Jan 9. 21(2):231-5. doi: 10.1128/aac.21.2.231.
      6: Pontzer RE, Kaye D. Cefonicid: a long-acting, second-generation cephalosporin. Antimicrobial activity, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy. 1984 Nov-Dec;4(6):325-33. doi: 10.1002/j.1875-9114.1984.tb03392.x. 35(7):1360-4. doi: 10.1128/aac.35.7.1360.
      8: Karki SD, Bentley DW, Luzier A, Taylor C, Morse GD. Disposition of intramuscular cefonicid in elderly patients. J Am Geriatr Soc. 1993 Aug;41(8):808-10. doi: 10.1111/j.1532-5415.1993.tb06174.x. 6(4):271-2. 36(5):325-31. doi: 10.1159/000238784.

      合成参考文献


      参考文献:10.7164/antibiotics.33.85
      摘要:Grappel SF, Guarini JR, Actor P, Weisbach JA. Correlation of agar-disc-diffusion tests with minimum inhibitory concentrations of cefonicid (SK&F 75073) and cephalothin. J Antibiot (Tokyo). 1980 Jan;33(1):85–7. doi: 10.7164/antibiotics.33.85.
      参考文献:10.1002/(sici)1097-0347(199609/10)18:5<399::aid-hed2>3.0.co;2-0|10.1002/(sici)1097-0347(199609/10)18:5<399::aid-hed2>3.3.co;2-c
      摘要:Righi M, Manfredi R, Farneti G, Pasquini E, Cenacchi V. Short-term versus long-term antimicrobial prophylaxis in oncologic head and neck surgery. Head Neck. 1996 Sep;18(5):399–404. doi: 10.1002/(sici)1097-0347(199609/10)18:5<399::aid-hed2>3.0.co;2-0.
      参考文献:10.1128/jcm.30.8.2029-2032.1992
      摘要:Jorgensen JH, Barry AL, Doern GV, Ferraro MJ, Murray PR. Development of revised quality control limits for disk diffusion susceptibility tests of selected cephem antibiotics with Haemophilus influenzae and description of a new control strain. J Clin Microbiol. 1992 Aug;30(8):2029–32. doi: 10.1128/jcm.30.8.2029-2032.1992.
      摘要:Tullio V, Cuffini AM, Fazari S, Carlone NA. Cefonicid potentiation of human macrophage activity. Microbiologica. 1992 Jul;15(3):219–26.
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知